It was purchased for $8.7 Billion...and it failed miserably.
AbbVie purchases neuroscience developer Cerevel for $8.7 billion
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion acquisition of Cerevel Therapeutics.
In Phase 2 studies, patients on different doses of the drug, called emraclidine, did not experience significant improvements on a test called the Positive and Negative Syndrome Scale (PANSS) compared with the placebo group.
Market Data 
Markets 
AI
